Clinical Trial Detail

NCT ID NCT02743819
Title Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Indications

melanoma

Therapies

Ipilimumab + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.